0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Parkinsons Disease Drugs Market Insights, Forecast to 2029
Published Date: August 2023
|
Report Code: QYRE-Auto-13P10093
Home | Market Reports | Health| Health Conditions| Neurological Conditions
Global Parkinsons Disease Drugs Market Insights Forecast to 2028
BUY CHAPTERS

Global Parkinsons Disease Drugs Market Insights, Forecast to 2029

Code: QYRE-Auto-13P10093
Report
August 2023
Pages:109
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Parkinsons Disease Drugs Market Size

The global Parkinsons Disease Drugs market is projected to grow from US$ 5883.6 million in 2023 to US$ 8440.9 million by 2029, at a Compound Annual Growth Rate (CAGR) of 6.2% during the forecast period.

Parkinsons Disease Drugs Market

Parkinsons Disease Drugs Market

Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.
Global Parkinson Disease Drug key players include Merck, Akorn, GSK, Boehringer Ingelheim, Teva Pharmaceutical, etc.

Report Includes:

This report presents an overview of global market for Parkinsons Disease Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Parkinsons Disease Drugs, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Parkinsons Disease Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Parkinsons Disease Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global Parkinsons Disease Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2029. Evaluation and forecast the market size for Parkinsons Disease Drugs sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Johnson & Johnson, Gilead Sciences, Pacira, Sun Pharmaceutical, Luye Pharma, Sigma-Tau Group, Fudan-Zhangjiang, Teva Pharmaceutical and CSPC, etc.

Scope of Parkinsons Disease Drugs Market Report

Report Metric Details
Report Name Parkinsons Disease Drugs Market
Accounted market size in 2023 US$ 5883.6 million
Forecasted market size in 2029 US$ 8440.9 million
CAGR 6.2
Base Year 2023
Forecasted years 2023 - 2029
Segment by Type
  • Clinical
  • Experiment
Segment by Application
  • Treament
  • Prevention
Segment by Region
  • US & Canada
  • U.S.
  • Canada
  • China
  • Asia (excluding China)
  • Japan
  • South Korea
  • China Taiwan
  • Southeast Asia
  • India
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Middle East, Africa, Latin America
  • Brazil
  • Mexico
  • Turkey
  • Israel
  • GCC Countries
By Company Johnson & Johnson, Gilead Sciences, Pacira, Sun Pharmaceutical, Luye Pharma, Sigma-Tau Group, Fudan-Zhangjiang, Teva Pharmaceutical, CSPC, Novartis, Kingond Pharm
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Sales (consumption), revenue of Parkinsons Disease Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 3: Detailed analysis of Parkinsons Disease Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
  • Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
  • Chapter 8: China by type, by application sales and revenue for each segment.
  • Chapter 9: Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
  • Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
  • Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Parkinsons Disease Drugs sales, revenue, price, gross margin, and recent development, etc.
  • Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
  • Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 14: The main points and conclusions of the report.

FAQ for this report

How fast is Parkinsons Disease Drugs Market growing?

Ans: The Parkinsons Disease Drugs Market witnessing a CAGR of 6.2 during the forecast period 2023-2029.

What is the Parkinsons Disease Drugs Market size in 2029?

Ans: The global Parkinsons Disease Drugs market is projected to grow from US$ 5883.6 million in 2023 to US$ 8440.9 million by 2029, at a Compound Annual Growth Rate (CAGR) of 6.2% during the forecast period.

Who are the main players in the Parkinsons Disease Drugs Market report?

Ans: The main players in the Parkinsons Disease Drugs Market are Johnson & Johnson, Gilead Sciences, Pacira, Sun Pharmaceutical, Luye Pharma, Sigma-Tau Group, Fudan-Zhangjiang, Teva Pharmaceutical, CSPC, Novartis, Kingond Pharm

What are the Application segmentation covered in the Parkinsons Disease Drugs Market report?

Ans: The Applications covered in the Parkinsons Disease Drugs Market report are Treament, Prevention

What are the Type segmentation covered in the Parkinsons Disease Drugs Market report?

Ans: The Types covered in the Parkinsons Disease Drugs Market report are Clinical, Experiment

1 Study Coverage
1.1 Parkinsons Disease Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Parkinsons Disease Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Clinical
1.2.3 Experiment
1.3 Market by Application
1.3.1 Global Parkinsons Disease Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Treament
1.3.3 Prevention
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Parkinsons Disease Drugs Sales Estimates and Forecasts 2018-2029
2.2 Global Parkinsons Disease Drugs Revenue by Region
2.2.1 Global Parkinsons Disease Drugs Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Parkinsons Disease Drugs Revenue by Region (2018-2023)
2.2.3 Global Parkinsons Disease Drugs Revenue by Region (2024-2029)
2.2.4 Global Parkinsons Disease Drugs Revenue Market Share by Region (2018-2029)
2.3 Global Parkinsons Disease Drugs Sales Estimates and Forecasts 2018-2029
2.4 Global Parkinsons Disease Drugs Sales by Region
2.4.1 Global Parkinsons Disease Drugs Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Parkinsons Disease Drugs Sales by Region (2018-2023)
2.4.3 Global Parkinsons Disease Drugs Sales by Region (2024-2029)
2.4.4 Global Parkinsons Disease Drugs Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Parkinsons Disease Drugs Sales by Manufacturers
3.1.1 Global Parkinsons Disease Drugs Sales by Manufacturers (2018-2023)
3.1.2 Global Parkinsons Disease Drugs Sales Market Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Parkinsons Disease Drugs in 2022
3.2 Global Parkinsons Disease Drugs Revenue by Manufacturers
3.2.1 Global Parkinsons Disease Drugs Revenue by Manufacturers (2018-2023)
3.2.2 Global Parkinsons Disease Drugs Revenue Market Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Parkinsons Disease Drugs Revenue in 2022
3.3 Global Key Players of Parkinsons Disease Drugs, Industry Ranking, 2021 VS 2022 VS 2023
3.4 Global Parkinsons Disease Drugs Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Parkinsons Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Parkinsons Disease Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Parkinsons Disease Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Parkinsons Disease Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Parkinsons Disease Drugs Sales by Type
4.1.1 Global Parkinsons Disease Drugs Historical Sales by Type (2018-2023)
4.1.2 Global Parkinsons Disease Drugs Forecasted Sales by Type (2024-2029)
4.1.3 Global Parkinsons Disease Drugs Sales Market Share by Type (2018-2029)
4.2 Global Parkinsons Disease Drugs Revenue by Type
4.2.1 Global Parkinsons Disease Drugs Historical Revenue by Type (2018-2023)
4.2.2 Global Parkinsons Disease Drugs Forecasted Revenue by Type (2024-2029)
4.2.3 Global Parkinsons Disease Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Parkinsons Disease Drugs Price by Type
4.3.1 Global Parkinsons Disease Drugs Price by Type (2018-2023)
4.3.2 Global Parkinsons Disease Drugs Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Parkinsons Disease Drugs Sales by Application
5.1.1 Global Parkinsons Disease Drugs Historical Sales by Application (2018-2023)
5.1.2 Global Parkinsons Disease Drugs Forecasted Sales by Application (2024-2029)
5.1.3 Global Parkinsons Disease Drugs Sales Market Share by Application (2018-2029)
5.2 Global Parkinsons Disease Drugs Revenue by Application
5.2.1 Global Parkinsons Disease Drugs Historical Revenue by Application (2018-2023)
5.2.2 Global Parkinsons Disease Drugs Forecasted Revenue by Application (2024-2029)
5.2.3 Global Parkinsons Disease Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Parkinsons Disease Drugs Price by Application
5.3.1 Global Parkinsons Disease Drugs Price by Application (2018-2023)
5.3.2 Global Parkinsons Disease Drugs Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Parkinsons Disease Drugs Market Size by Type
6.1.1 US & Canada Parkinsons Disease Drugs Sales by Type (2018-2029)
6.1.2 US & Canada Parkinsons Disease Drugs Revenue by Type (2018-2029)
6.2 US & Canada Parkinsons Disease Drugs Market Size by Application
6.2.1 US & Canada Parkinsons Disease Drugs Sales by Application (2018-2029)
6.2.2 US & Canada Parkinsons Disease Drugs Revenue by Application (2018-2029)
6.3 US & Canada Parkinsons Disease Drugs Market Size by Country
6.3.1 US & Canada Parkinsons Disease Drugs Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Parkinsons Disease Drugs Sales by Country (2018-2029)
6.3.3 US & Canada Parkinsons Disease Drugs Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Parkinsons Disease Drugs Market Size by Type
7.1.1 Europe Parkinsons Disease Drugs Sales by Type (2018-2029)
7.1.2 Europe Parkinsons Disease Drugs Revenue by Type (2018-2029)
7.2 Europe Parkinsons Disease Drugs Market Size by Application
7.2.1 Europe Parkinsons Disease Drugs Sales by Application (2018-2029)
7.2.2 Europe Parkinsons Disease Drugs Revenue by Application (2018-2029)
7.3 Europe Parkinsons Disease Drugs Market Size by Country
7.3.1 Europe Parkinsons Disease Drugs Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Parkinsons Disease Drugs Sales by Country (2018-2029)
7.3.3 Europe Parkinsons Disease Drugs Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Parkinsons Disease Drugs Market Size
8.1.1 China Parkinsons Disease Drugs Sales (2018-2029)
8.1.2 China Parkinsons Disease Drugs Revenue (2018-2029)
8.2 China Parkinsons Disease Drugs Market Size by Application
8.2.1 China Parkinsons Disease Drugs Sales by Application (2018-2029)
8.2.2 China Parkinsons Disease Drugs Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Parkinsons Disease Drugs Market Size by Type
9.1.1 Asia Parkinsons Disease Drugs Sales by Type (2018-2029)
9.1.2 Asia Parkinsons Disease Drugs Revenue by Type (2018-2029)
9.2 Asia Parkinsons Disease Drugs Market Size by Application
9.2.1 Asia Parkinsons Disease Drugs Sales by Application (2018-2029)
9.2.2 Asia Parkinsons Disease Drugs Revenue by Application (2018-2029)
9.3 Asia Parkinsons Disease Drugs Sales by Region
9.3.1 Asia Parkinsons Disease Drugs Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Parkinsons Disease Drugs Revenue by Region (2018-2029)
9.3.3 Asia Parkinsons Disease Drugs Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Parkinsons Disease Drugs Market Size by Type
10.1.1 Middle East, Africa and Latin America Parkinsons Disease Drugs Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Parkinsons Disease Drugs Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Parkinsons Disease Drugs Market Size by Application
10.2.1 Middle East, Africa and Latin America Parkinsons Disease Drugs Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Parkinsons Disease Drugs Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Parkinsons Disease Drugs Sales by Country
10.3.1 Middle East, Africa and Latin America Parkinsons Disease Drugs Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Parkinsons Disease Drugs Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Parkinsons Disease Drugs Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Information
11.1.2 Johnson & Johnson Overview
11.1.3 Johnson & Johnson Parkinsons Disease Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 Johnson & Johnson Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Johnson & Johnson Recent Developments
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Information
11.2.2 Gilead Sciences Overview
11.2.3 Gilead Sciences Parkinsons Disease Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 Gilead Sciences Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Gilead Sciences Recent Developments
11.3 Pacira
11.3.1 Pacira Company Information
11.3.2 Pacira Overview
11.3.3 Pacira Parkinsons Disease Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 Pacira Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Pacira Recent Developments
11.4 Sun Pharmaceutical
11.4.1 Sun Pharmaceutical Company Information
11.4.2 Sun Pharmaceutical Overview
11.4.3 Sun Pharmaceutical Parkinsons Disease Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Sun Pharmaceutical Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Sun Pharmaceutical Recent Developments
11.5 Luye Pharma
11.5.1 Luye Pharma Company Information
11.5.2 Luye Pharma Overview
11.5.3 Luye Pharma Parkinsons Disease Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 Luye Pharma Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Luye Pharma Recent Developments
11.6 Sigma-Tau Group
11.6.1 Sigma-Tau Group Company Information
11.6.2 Sigma-Tau Group Overview
11.6.3 Sigma-Tau Group Parkinsons Disease Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.6.4 Sigma-Tau Group Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Sigma-Tau Group Recent Developments
11.7 Fudan-Zhangjiang
11.7.1 Fudan-Zhangjiang Company Information
11.7.2 Fudan-Zhangjiang Overview
11.7.3 Fudan-Zhangjiang Parkinsons Disease Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.7.4 Fudan-Zhangjiang Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Fudan-Zhangjiang Recent Developments
11.8 Teva Pharmaceutical
11.8.1 Teva Pharmaceutical Company Information
11.8.2 Teva Pharmaceutical Overview
11.8.3 Teva Pharmaceutical Parkinsons Disease Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.8.4 Teva Pharmaceutical Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Teva Pharmaceutical Recent Developments
11.9 CSPC
11.9.1 CSPC Company Information
11.9.2 CSPC Overview
11.9.3 CSPC Parkinsons Disease Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.9.4 CSPC Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 CSPC Recent Developments
11.10 Novartis
11.10.1 Novartis Company Information
11.10.2 Novartis Overview
11.10.3 Novartis Parkinsons Disease Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.10.4 Novartis Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Novartis Recent Developments
11.11 Kingond Pharm
11.11.1 Kingond Pharm Company Information
11.11.2 Kingond Pharm Overview
11.11.3 Kingond Pharm Parkinsons Disease Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.11.4 Kingond Pharm Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Kingond Pharm Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Parkinsons Disease Drugs Industry Chain Analysis
12.2 Parkinsons Disease Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Parkinsons Disease Drugs Production Mode & Process
12.4 Parkinsons Disease Drugs Sales and Marketing
12.4.1 Parkinsons Disease Drugs Sales Channels
12.4.2 Parkinsons Disease Drugs Distributors
12.5 Parkinsons Disease Drugs Customers
13 Market Dynamics
13.1 Parkinsons Disease Drugs Industry Trends
13.2 Parkinsons Disease Drugs Market Drivers
13.3 Parkinsons Disease Drugs Market Challenges
13.4 Parkinsons Disease Drugs Market Restraints
14 Key Findings in The Global Parkinsons Disease Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
    Table 1. Global Parkinsons Disease Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
    Table 2. Major Manufacturers of Clinical
    Table 3. Major Manufacturers of Experiment
    Table 4. Global Parkinsons Disease Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
    Table 5. Global Parkinsons Disease Drugs Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
    Table 6. Global Parkinsons Disease Drugs Revenue by Region (2018-2023) & (US$ Million)
    Table 7. Global Parkinsons Disease Drugs Revenue by Region (2024-2029) & (US$ Million)
    Table 8. Global Parkinsons Disease Drugs Revenue Market Share by Region (2018-2023)
    Table 9. Global Parkinsons Disease Drugs Revenue Market Share by Region (2024-2029)
    Table 10. Global Parkinsons Disease Drugs Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
    Table 11. Global Parkinsons Disease Drugs Sales by Region (2018-2023) & (K Units)
    Table 12. Global Parkinsons Disease Drugs Sales by Region (2024-2029) & (K Units)
    Table 13. Global Parkinsons Disease Drugs Sales Market Share by Region (2018-2023)
    Table 14. Global Parkinsons Disease Drugs Sales Market Share by Region (2024-2029)
    Table 15. Global Parkinsons Disease Drugs Sales by Manufacturers (2018-2023) & (K Units)
    Table 16. Global Parkinsons Disease Drugs Sales Share by Manufacturers (2018-2023)
    Table 17. Global Parkinsons Disease Drugs Revenue by Manufacturers (2018-2023) & (US$ Million)
    Table 18. Global Parkinsons Disease Drugs Revenue Share by Manufacturers (2018-2023)
    Table 19. Global Key Players of Parkinsons Disease Drugs, Industry Ranking, 2021 VS 2022 VS 2023
    Table 20. Parkinsons Disease Drugs Price by Manufacturers 2018-2023 (USD/Unit)
    Table 21. Global Parkinsons Disease Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 22. Global Parkinsons Disease Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Parkinsons Disease Drugs as of 2022)
    Table 23. Global Key Manufacturers of Parkinsons Disease Drugs, Manufacturing Base Distribution and Headquarters
    Table 24. Global Key Manufacturers of Parkinsons Disease Drugs, Product Offered and Application
    Table 25. Global Key Manufacturers of Parkinsons Disease Drugs, Date of Enter into This Industry
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Parkinsons Disease Drugs Sales by Type (2018-2023) & (K Units)
    Table 28. Global Parkinsons Disease Drugs Sales by Type (2024-2029) & (K Units)
    Table 29. Global Parkinsons Disease Drugs Sales Share by Type (2018-2023)
    Table 30. Global Parkinsons Disease Drugs Sales Share by Type (2024-2029)
    Table 31. Global Parkinsons Disease Drugs Revenue by Type (2018-2023) & (US$ Million)
    Table 32. Global Parkinsons Disease Drugs Revenue by Type (2024-2029) & (US$ Million)
    Table 33. Global Parkinsons Disease Drugs Revenue Share by Type (2018-2023)
    Table 34. Global Parkinsons Disease Drugs Revenue Share by Type (2024-2029)
    Table 35. Parkinsons Disease Drugs Price by Type (2018-2023) & (USD/Unit)
    Table 36. Global Parkinsons Disease Drugs Price Forecast by Type (2024-2029) & (USD/Unit)
    Table 37. Global Parkinsons Disease Drugs Sales by Application (2018-2023) & (K Units)
    Table 38. Global Parkinsons Disease Drugs Sales by Application (2024-2029) & (K Units)
    Table 39. Global Parkinsons Disease Drugs Sales Share by Application (2018-2023)
    Table 40. Global Parkinsons Disease Drugs Sales Share by Application (2024-2029)
    Table 41. Global Parkinsons Disease Drugs Revenue by Application (2018-2023) & (US$ Million)
    Table 42. Global Parkinsons Disease Drugs Revenue by Application (2024-2029) & (US$ Million)
    Table 43. Global Parkinsons Disease Drugs Revenue Share by Application (2018-2023)
    Table 44. Global Parkinsons Disease Drugs Revenue Share by Application (2024-2029)
    Table 45. Parkinsons Disease Drugs Price by Application (2018-2023) & (USD/Unit)
    Table 46. Global Parkinsons Disease Drugs Price Forecast by Application (2024-2029) & (USD/Unit)
    Table 47. US & Canada Parkinsons Disease Drugs Sales by Type (2018-2023) & (K Units)
    Table 48. US & Canada Parkinsons Disease Drugs Sales by Type (2024-2029) & (K Units)
    Table 49. US & Canada Parkinsons Disease Drugs Revenue by Type (2018-2023) & (US$ Million)
    Table 50. US & Canada Parkinsons Disease Drugs Revenue by Type (2024-2029) & (US$ Million)
    Table 51. US & Canada Parkinsons Disease Drugs Sales by Application (2018-2023) & (K Units)
    Table 52. US & Canada Parkinsons Disease Drugs Sales by Application (2024-2029) & (K Units)
    Table 53. US & Canada Parkinsons Disease Drugs Revenue by Application (2018-2023) & (US$ Million)
    Table 54. US & Canada Parkinsons Disease Drugs Revenue by Application (2024-2029) & (US$ Million)
    Table 55. US & Canada Parkinsons Disease Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 56. US & Canada Parkinsons Disease Drugs Revenue by Country (2018-2023) & (US$ Million)
    Table 57. US & Canada Parkinsons Disease Drugs Revenue by Country (2024-2029) & (US$ Million)
    Table 58. US & Canada Parkinsons Disease Drugs Sales by Country (2018-2023) & (K Units)
    Table 59. US & Canada Parkinsons Disease Drugs Sales by Country (2024-2029) & (K Units)
    Table 60. Europe Parkinsons Disease Drugs Sales by Type (2018-2023) & (K Units)
    Table 61. Europe Parkinsons Disease Drugs Sales by Type (2024-2029) & (K Units)
    Table 62. Europe Parkinsons Disease Drugs Revenue by Type (2018-2023) & (US$ Million)
    Table 63. Europe Parkinsons Disease Drugs Revenue by Type (2024-2029) & (US$ Million)
    Table 64. Europe Parkinsons Disease Drugs Sales by Application (2018-2023) & (K Units)
    Table 65. Europe Parkinsons Disease Drugs Sales by Application (2024-2029) & (K Units)
    Table 66. Europe Parkinsons Disease Drugs Revenue by Application (2018-2023) & (US$ Million)
    Table 67. Europe Parkinsons Disease Drugs Revenue by Application (2024-2029) & (US$ Million)
    Table 68. Europe Parkinsons Disease Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 69. Europe Parkinsons Disease Drugs Revenue by Country (2018-2023) & (US$ Million)
    Table 70. Europe Parkinsons Disease Drugs Revenue by Country (2024-2029) & (US$ Million)
    Table 71. Europe Parkinsons Disease Drugs Sales by Country (2018-2023) & (K Units)
    Table 72. Europe Parkinsons Disease Drugs Sales by Country (2024-2029) & (K Units)
    Table 73. China Parkinsons Disease Drugs Sales by Type (2018-2023) & (K Units)
    Table 74. China Parkinsons Disease Drugs Sales by Type (2024-2029) & (K Units)
    Table 75. China Parkinsons Disease Drugs Revenue by Type (2018-2023) & (US$ Million)
    Table 76. China Parkinsons Disease Drugs Revenue by Type (2024-2029) & (US$ Million)
    Table 77. China Parkinsons Disease Drugs Sales by Application (2018-2023) & (K Units)
    Table 78. China Parkinsons Disease Drugs Sales by Application (2024-2029) & (K Units)
    Table 79. China Parkinsons Disease Drugs Revenue by Application (2018-2023) & (US$ Million)
    Table 80. China Parkinsons Disease Drugs Revenue by Application (2024-2029) & (US$ Million)
    Table 81. Asia Parkinsons Disease Drugs Sales by Type (2018-2023) & (K Units)
    Table 82. Asia Parkinsons Disease Drugs Sales by Type (2024-2029) & (K Units)
    Table 83. Asia Parkinsons Disease Drugs Revenue by Type (2018-2023) & (US$ Million)
    Table 84. Asia Parkinsons Disease Drugs Revenue by Type (2024-2029) & (US$ Million)
    Table 85. Asia Parkinsons Disease Drugs Sales by Application (2018-2023) & (K Units)
    Table 86. Asia Parkinsons Disease Drugs Sales by Application (2024-2029) & (K Units)
    Table 87. Asia Parkinsons Disease Drugs Revenue by Application (2018-2023) & (US$ Million)
    Table 88. Asia Parkinsons Disease Drugs Revenue by Application (2024-2029) & (US$ Million)
    Table 89. Asia Parkinsons Disease Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 90. Asia Parkinsons Disease Drugs Revenue by Region (2018-2023) & (US$ Million)
    Table 91. Asia Parkinsons Disease Drugs Revenue by Region (2024-2029) & (US$ Million)
    Table 92. Asia Parkinsons Disease Drugs Sales by Region (2018-2023) & (K Units)
    Table 93. Asia Parkinsons Disease Drugs Sales by Region (2024-2029) & (K Units)
    Table 94. Middle East, Africa and Latin America Parkinsons Disease Drugs Sales by Type (2018-2023) & (K Units)
    Table 95. Middle East, Africa and Latin America Parkinsons Disease Drugs Sales by Type (2024-2029) & (K Units)
    Table 96. Middle East, Africa and Latin America Parkinsons Disease Drugs Revenue by Type (2018-2023) & (US$ Million)
    Table 97. Middle East, Africa and Latin America Parkinsons Disease Drugs Revenue by Type (2024-2029) & (US$ Million)
    Table 98. Middle East, Africa and Latin America Parkinsons Disease Drugs Sales by Application (2018-2023) & (K Units)
    Table 99. Middle East, Africa and Latin America Parkinsons Disease Drugs Sales by Application (2024-2029) & (K Units)
    Table 100. Middle East, Africa and Latin America Parkinsons Disease Drugs Revenue by Application (2018-2023) & (US$ Million)
    Table 101. Middle East, Africa and Latin America Parkinsons Disease Drugs Revenue by Application (2024-2029) & (US$ Million)
    Table 102. Middle East, Africa and Latin America Parkinsons Disease Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 103. Middle East, Africa and Latin America Parkinsons Disease Drugs Revenue by Country (2018-2023) & (US$ Million)
    Table 104. Middle East, Africa and Latin America Parkinsons Disease Drugs Revenue by Country (2024-2029) & (US$ Million)
    Table 105. Middle East, Africa and Latin America Parkinsons Disease Drugs Sales by Country (2018-2023) & (K Units)
    Table 106. Middle East, Africa and Latin America Parkinsons Disease Drugs Sales by Country (2024-2029) & (K Units)
    Table 107. Johnson & Johnson Company Information
    Table 108. Johnson & Johnson Description and Major Businesses
    Table 109. Johnson & Johnson Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 110. Johnson & Johnson Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 111. Johnson & Johnson Recent Developments
    Table 112. Gilead Sciences Company Information
    Table 113. Gilead Sciences Description and Major Businesses
    Table 114. Gilead Sciences Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 115. Gilead Sciences Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 116. Gilead Sciences Recent Developments
    Table 117. Pacira Company Information
    Table 118. Pacira Description and Major Businesses
    Table 119. Pacira Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 120. Pacira Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 121. Pacira Recent Developments
    Table 122. Sun Pharmaceutical Company Information
    Table 123. Sun Pharmaceutical Description and Major Businesses
    Table 124. Sun Pharmaceutical Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 125. Sun Pharmaceutical Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 126. Sun Pharmaceutical Recent Developments
    Table 127. Luye Pharma Company Information
    Table 128. Luye Pharma Description and Major Businesses
    Table 129. Luye Pharma Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 130. Luye Pharma Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 131. Luye Pharma Recent Developments
    Table 132. Sigma-Tau Group Company Information
    Table 133. Sigma-Tau Group Description and Major Businesses
    Table 134. Sigma-Tau Group Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 135. Sigma-Tau Group Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 136. Sigma-Tau Group Recent Developments
    Table 137. Fudan-Zhangjiang Company Information
    Table 138. Fudan-Zhangjiang Description and Major Businesses
    Table 139. Fudan-Zhangjiang Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 140. Fudan-Zhangjiang Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 141. Fudan-Zhangjiang Recent Developments
    Table 142. Teva Pharmaceutical Company Information
    Table 143. Teva Pharmaceutical Description and Major Businesses
    Table 144. Teva Pharmaceutical Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 145. Teva Pharmaceutical Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 146. Teva Pharmaceutical Recent Developments
    Table 147. CSPC Company Information
    Table 148. CSPC Description and Major Businesses
    Table 149. CSPC Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 150. CSPC Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 151. CSPC Recent Developments
    Table 152. Novartis Company Information
    Table 153. Novartis Description and Major Businesses
    Table 154. Novartis Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 155. Novartis Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 156. Novartis Recent Developments
    Table 157. Kingond Pharm Company Information
    Table 158. Kingond Pharm Description and Major Businesses
    Table 159. Kingond Pharm Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 160. Kingond Pharm Parkinsons Disease Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 161. Kingond Pharm Recent Developments
    Table 162. Key Raw Materials Lists
    Table 163. Raw Materials Key Suppliers Lists
    Table 164. Parkinsons Disease Drugs Distributors List
    Table 165. Parkinsons Disease Drugs Customers List
    Table 166. Parkinsons Disease Drugs Market Trends
    Table 167. Parkinsons Disease Drugs Market Drivers
    Table 168. Parkinsons Disease Drugs Market Challenges
    Table 169. Parkinsons Disease Drugs Market Restraints
    Table 170. Research Programs/Design for This Report
    Table 171. Key Data Information from Secondary Sources
    Table 172. Key Data Information from Primary Sources
List of Figures
    Figure 1. Parkinsons Disease Drugs Product Picture
    Figure 2. Global Parkinsons Disease Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
    Figure 3. Global Parkinsons Disease Drugs Market Share by Type in 2022 & 2029
    Figure 4. Clinical Product Picture
    Figure 5. Experiment Product Picture
    Figure 6. Global Parkinsons Disease Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
    Figure 7. Global Parkinsons Disease Drugs Market Share by Application in 2022 & 2029
    Figure 8. Treament
    Figure 9. Prevention
    Figure 10. Parkinsons Disease Drugs Report Years Considered
    Figure 11. Global Parkinsons Disease Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
    Figure 12. Global Parkinsons Disease Drugs Revenue 2018-2029 (US$ Million)
    Figure 13. Global Parkinsons Disease Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2029
    Figure 14. Global Parkinsons Disease Drugs Revenue Market Share by Region (2018-2029)
    Figure 15. Global Parkinsons Disease Drugs Sales 2018-2029 ((K Units)
    Figure 16. Global Parkinsons Disease Drugs Sales Market Share by Region (2018-2029)
    Figure 17. US & Canada Parkinsons Disease Drugs Sales YoY (2018-2029) & (K Units)
    Figure 18. US & Canada Parkinsons Disease Drugs Revenue YoY (2018-2029) & (US$ Million)
    Figure 19. Europe Parkinsons Disease Drugs Sales YoY (2018-2029) & (K Units)
    Figure 20. Europe Parkinsons Disease Drugs Revenue YoY (2018-2029) & (US$ Million)
    Figure 21. China Parkinsons Disease Drugs Sales YoY (2018-2029) & (K Units)
    Figure 22. China Parkinsons Disease Drugs Revenue YoY (2018-2029) & (US$ Million)
    Figure 23. Asia (excluding China) Parkinsons Disease Drugs Sales YoY (2018-2029) & (K Units)
    Figure 24. Asia (excluding China) Parkinsons Disease Drugs Revenue YoY (2018-2029) & (US$ Million)
    Figure 25. Middle East, Africa and Latin America Parkinsons Disease Drugs Sales YoY (2018-2029) & (K Units)
    Figure 26. Middle East, Africa and Latin America Parkinsons Disease Drugs Revenue YoY (2018-2029) & (US$ Million)
    Figure 27. The Parkinsons Disease Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
    Figure 28. The Top 5 and 10 Largest Manufacturers of Parkinsons Disease Drugs in the World: Market Share by Parkinsons Disease Drugs Revenue in 2022
    Figure 29. Global Parkinsons Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
    Figure 30. Global Parkinsons Disease Drugs Sales Market Share by Type (2018-2029)
    Figure 31. Global Parkinsons Disease Drugs Revenue Market Share by Type (2018-2029)
    Figure 32. Global Parkinsons Disease Drugs Sales Market Share by Application (2018-2029)
    Figure 33. Global Parkinsons Disease Drugs Revenue Market Share by Application (2018-2029)
    Figure 34. US & Canada Parkinsons Disease Drugs Sales Market Share by Type (2018-2029)
    Figure 35. US & Canada Parkinsons Disease Drugs Revenue Market Share by Type (2018-2029)
    Figure 36. US & Canada Parkinsons Disease Drugs Sales Market Share by Application (2018-2029)
    Figure 37. US & Canada Parkinsons Disease Drugs Revenue Market Share by Application (2018-2029)
    Figure 38. US & Canada Parkinsons Disease Drugs Revenue Share by Country (2018-2029)
    Figure 39. US & Canada Parkinsons Disease Drugs Sales Share by Country (2018-2029)
    Figure 40. U.S. Parkinsons Disease Drugs Revenue (2018-2029) & (US$ Million)
    Figure 41. Canada Parkinsons Disease Drugs Revenue (2018-2029) & (US$ Million)
    Figure 42. Europe Parkinsons Disease Drugs Sales Market Share by Type (2018-2029)
    Figure 43. Europe Parkinsons Disease Drugs Revenue Market Share by Type (2018-2029)
    Figure 44. Europe Parkinsons Disease Drugs Sales Market Share by Application (2018-2029)
    Figure 45. Europe Parkinsons Disease Drugs Revenue Market Share by Application (2018-2029)
    Figure 46. Europe Parkinsons Disease Drugs Revenue Share by Country (2018-2029)
    Figure 47. Europe Parkinsons Disease Drugs Sales Share by Country (2018-2029)
    Figure 48. Germany Parkinsons Disease Drugs Revenue (2018-2029) & (US$ Million)
    Figure 49. France Parkinsons Disease Drugs Revenue (2018-2029) & (US$ Million)
    Figure 50. U.K. Parkinsons Disease Drugs Revenue (2018-2029) & (US$ Million)
    Figure 51. Italy Parkinsons Disease Drugs Revenue (2018-2029) & (US$ Million)
    Figure 52. Russia Parkinsons Disease Drugs Revenue (2018-2029) & (US$ Million)
    Figure 53. China Parkinsons Disease Drugs Sales Market Share by Type (2018-2029)
    Figure 54. China Parkinsons Disease Drugs Revenue Market Share by Type (2018-2029)
    Figure 55. China Parkinsons Disease Drugs Sales Market Share by Application (2018-2029)
    Figure 56. China Parkinsons Disease Drugs Revenue Market Share by Application (2018-2029)
    Figure 57. Asia Parkinsons Disease Drugs Sales Market Share by Type (2018-2029)
    Figure 58. Asia Parkinsons Disease Drugs Revenue Market Share by Type (2018-2029)
    Figure 59. Asia Parkinsons Disease Drugs Sales Market Share by Application (2018-2029)
    Figure 60. Asia Parkinsons Disease Drugs Revenue Market Share by Application (2018-2029)
    Figure 61. Asia Parkinsons Disease Drugs Revenue Share by Region (2018-2029)
    Figure 62. Asia Parkinsons Disease Drugs Sales Share by Region (2018-2029)
    Figure 63. Japan Parkinsons Disease Drugs Revenue (2018-2029) & (US$ Million)
    Figure 64. South Korea Parkinsons Disease Drugs Revenue (2018-2029) & (US$ Million)
    Figure 65. China Taiwan Parkinsons Disease Drugs Revenue (2018-2029) & (US$ Million)
    Figure 66. Southeast Asia Parkinsons Disease Drugs Revenue (2018-2029) & (US$ Million)
    Figure 67. India Parkinsons Disease Drugs Revenue (2018-2029) & (US$ Million)
    Figure 68. Middle East, Africa and Latin America Parkinsons Disease Drugs Sales Market Share by Type (2018-2029)
    Figure 69. Middle East, Africa and Latin America Parkinsons Disease Drugs Revenue Market Share by Type (2018-2029)
    Figure 70. Middle East, Africa and Latin America Parkinsons Disease Drugs Sales Market Share by Application (2018-2029)
    Figure 71. Middle East, Africa and Latin America Parkinsons Disease Drugs Revenue Market Share by Application (2018-2029)
    Figure 72. Middle East, Africa and Latin America Parkinsons Disease Drugs Revenue Share by Country (2018-2029)
    Figure 73. Middle East, Africa and Latin America Parkinsons Disease Drugs Sales Share by Country (2018-2029)
    Figure 74. Brazil Parkinsons Disease Drugs Revenue (2018-2029) & (US$ Million)
    Figure 75. Mexico Parkinsons Disease Drugs Revenue (2018-2029) & (US$ Million)
    Figure 76. Turkey Parkinsons Disease Drugs Revenue (2018-2029) & (US$ Million)
    Figure 77. Israel Parkinsons Disease Drugs Revenue (2018-2029) & (US$ Million)
    Figure 78. GCC Countries Parkinsons Disease Drugs Revenue (2018-2029) & (US$ Million)
    Figure 79. Parkinsons Disease Drugs Value Chain
    Figure 80. Parkinsons Disease Drugs Production Process
    Figure 81. Channels of Distribution
    Figure 82. Distributors Profiles
    Figure 83. Bottom-up and Top-down Approaches for This Report
    Figure 84. Data Triangulation
    Figure 85. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Progressive Supranuclear Palsy Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-37D8375
Fri Feb 23 00:00:00 UTC 2024

Add to Cart

Global Autism Spectrum Disorder Diagnosis and Therapeutics Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-38J12701
Fri Feb 23 00:00:00 UTC 2024

Add to Cart

Global Essential Tremor Treatment Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-041
Fri Feb 23 00:00:00 UTC 2024

Add to Cart

Global Developmental and Epileptic Encephalopathies (DEE) Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-22N8285
Thu Feb 22 00:00:00 UTC 2024

Add to Cart